VIDA blog posts
With the rising concerns of COVID-19 disease (SARS-CoV-2 coronavirus) spreading throughout the global community, the VIDA team wants to assure our customers and partners that we have taken steps to adapt to the worldwide crisis. The health and wellbeing of our employees, partners, customers, and the community is our top
Coralville, IA (March 12, 2020) — VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, today announced an $11M initial close of its Series C financing. The investment was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures. Existing investors including
There is a lot going on right now in the world of thoracic imaging, from coronavirus screening to AI to burnout. To get an insider's perspective on these topics and more, we sat down "virtually" with John Newell, MD FACR for a Q&A. About John Newell, MD Dr. Newell has
New Criteria Incorporates Quantitative CT Imaging in COPD Diagnosis Introduction In case you missed it, the COPDGene® investigators (112 pulmonary leaders) recently proposed a new methodology to diagnose and classify COPD, based on diagnostic information from over 10,000 smokers. This is big news! Today’s diagnostic methods for COPD have been
Coralville, IA (October 14, 2019) — VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing. With this agreement, VIDA’s LungPrint® analysis will be available through TeraRecon’s AI Interoperability platform, EnvoyAI, expanding
CORALVILLE, Iowa, Oct. 4, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, today announced the appointment of Erkan Akyuz as independent director. Mr. Akyuz will join VIDA's Board of Directors to help guide the company's growth initiatives with differentiated healthcare IT leadership and market expertise. Mr. Akyuz is the President
We were honored to "virtually" join Professor Felix Herth in a back-and-forth on the topic of endobronchial lung volume reduction (ELVR). For those in the field of interventional pulmonology, Prof. Herth needs no introduction as he's been at the forefront of clinical trials and clinical practice for many years. Our
$1M Investment Combined with Support from the State of Iowa Represents a Shared Vision to Transform Health Care through AI-Powered Innovation Coralville, IA (July 25, 2019) — VIDA Diagnostics, Inc. (VIDA) today announced a strategic partnership and investment from UnityPoint Health Ventures, part of the innovation arm of Iowa’s largest
Our CEO, Susan Wood, was recently interviewed by the Nuance team about LungPrint and the AI market in general. See the full interview on the What's Next Blog by Nuance. Click Here to Read More -end-
CORALVILLE, Iowa, June 25, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in pulmonary imaging analytics, today announced it has joined the Nuance AI Marketplace for Diagnostic Imaging as a technology partner. With this agreement, VIDA's LungPrint® Discovery analysis will be available through the Nuance AI Marketplace to 70 percent of all radiologists across
